UTRECHT, The Netherlands & PHILADELPHIA--(BUSINESS WIRE)--Lava Therapeutics B.V., today announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the ...

Janssen sued Teva in the US District Court for the District of New Jersey under the Hatch-Waxman Act after Teva filed an abbreviated new drug application (ANDA) on a generic version of Invega Sustenna ...

TITUSVILLE, N.J., April 3, 2017 /PRNewswire/ — Janssen Pharmaceuticals, Inc. (Janssen) today announced it has collaborated with Premier Inc. on the first and largest study of its kind to address an ...

Sun Pharmaceutical Industries was hit with a patent infringement lawsuit on July 9 in New Jersey District Court over its attempt to market generic versions of the antipsychotic drug Invega Sustenna.

Pharma Mar SA (ES:PHM) has released an update. Pharma Mar S.A. has received a significant payment of $10 million from Janssen Products LP, a subsidiary of Johnson & Johnson, marking a commercial ...

Millennium: The Takeda Oncology Company has announced that Takeda Pharmaceutcials Inc. has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for its cancer drug Velcade.

Article ‘Count’ and ‘Share’ for Janssen-Cilag Pharma GmbH based on listed parameters only. The articles listed below published by authors from Janssen-Cilag Pharma GmbH, organized by journal and ...

SOUTH SAN FRANCISCO, Calif., and VANCOUVER, Canada, April 12, 2023 /PRNewswire/ - ESSA Pharma Inc. (EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

A better understanding of early childhood microbiome shifts offers a unique window for detecting disease risk and intervening appropriately. In this webinar, Lloyd Bod and Nathaniel Robichaud will ...